On March 28, 2026, Alumis Inc. reported positive results from two Phase 3 trials of its drug envudeucitinib, highlighting significant improvements in skin clearance and symptoms of psoriasis. The company plans to submit a New Drug Application (NDA) later this year, emphasizing the drug’s potential as an oral therapy for plaque psoriasis.